https://www.selleckchem.com/pr....oducts/tecovirimat.h
8; 95% CI 5.2, 11.6), for probands and FDR diagnosed at age 45years (OR 6.9; 95% CI 3.9, 12.4), and for family history of MBC (OR 17.9; 95% CI 7.6, 42.1). Findings were confirmed in a sensitivity analysis of MBC cases who tested negative on a 25-gene pan-cancer panel. MBC patients without mutations in BRCA1/2 have significantly higher odds of a family history of breast cancer, suggesting the existence of unidentified MBC susceptibility alleles. MBC patients without mutations in BRCA1/2 have significantly higher odds of a family
Like
Comment
Share
